Literature DB >> 6391463

The influence of repeated administration of prazosin on its hypotensive effect and on renin release in conscious dogs. A comparison with urapidil.

A Beck, O Kraupp, S Bacher, R Seitelberger, G Raberger.   

Abstract

The effects of prazosin (0.1, 0.5 and 2.5 mg/kg, orally) on blood pressure, heart rate and PRA were investigated after acute and chronic administration in conscious, normotensive dogs. The acute administration of prazosin caused a reduction in both systolic and diastolic blood pressure and an increase in heart rate and PRA. After chronic administration, twice daily for four days, tolerance developed, which was not due to persistent counterregulation. On comparison with urapidil, another alpha-adrenoceptor antagonist, the hypotensive and counterregulatory response to acute administration were similar with both substances; the development of tolerance to prazosin after chronic administration contrasted with the results with urapidil.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6391463     DOI: 10.1007/BF01910487

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  22 in total

1.  The interaction between prazosin and clonidine at alpha-adrenoceptors in rats and cats.

Authors:  P B Timmermans; E Lam; P A Van Zwieten
Journal:  Eur J Pharmacol       Date:  1979-04-01       Impact factor: 4.432

2.  Comparative effects of prazosin and phenoxybenzamine on arterial blood pressure, heart rate, and plasma catecholamines in essential hypertension.

Authors:  J Mulvihill-Wilson; R M Graham; W Pettinger; C Muckleroy; S Anderson; F A Gaffney; C G Blomqvist
Journal:  J Cardiovasc Pharmacol       Date:  1979 Nov-Dec       Impact factor: 3.105

3.  Prazosin and presynaptic alpha-receptors in the cardioaccelerator nerve of the dog.

Authors:  J W Constantine; R A Weeks; W K McShane
Journal:  Eur J Pharmacol       Date:  1978-07-01       Impact factor: 4.432

4.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

5.  Blood pressure response and renin release following 4 days of treatment with dihydralazine and urapidil in conscious dogs.

Authors:  S Bacher; O Kraupp; A Beck; R Seitelberger; G Raberger
Journal:  Cardiovasc Res       Date:  1984-02       Impact factor: 10.787

6.  Acute tolerance to prazosin in conscious hypertensive rats: involvement of the renin-angiotensin system.

Authors:  R D Smith; D K Tessman; H R Kaplan
Journal:  J Pharmacol Exp Ther       Date:  1981-05       Impact factor: 4.030

7.  Prazosin depression of baroreflex function in hypertensive man.

Authors:  E H Sasso; D T O'Connor
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Effects of prazosin and phenoxybenzamine on alpha- and beta-receptor-mediated responses in intestinal resistance and capacitance vessels.

Authors:  P Patel; D Bose; C Greenway
Journal:  J Cardiovasc Pharmacol       Date:  1981 Sep-Oct       Impact factor: 3.105

9.  Alpha-receptor function changes after the first dose of prazosin.

Authors:  C von Bahr; B Lindström; P Seideman
Journal:  Clin Pharmacol Ther       Date:  1982-07       Impact factor: 6.875

10.  Prazosin does not alter canine renin release in response to systemic hypotension or intrarenal isoprenaline and prostaglandin I2 infusion.

Authors:  J G Gerber; A S Nies; R D Olson
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

View more
  2 in total

1.  Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans.

Authors:  J Vincent; W Dachman; T F Blaschke; B B Hoffman
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 2.  Urapidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H D Langtry; G J Mammen; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.